Furthermore, for enhanced glycemic control with a lower risk of hypoglycemia, options like incretin agents (DPP4 inhibitors or GLP1-RAs), SGLT2 inhibitors, acarbose, or pioglitazone were suggested as add-on therapies (41). Here, DPP4 is linked to Hypoglycemia.